133 related articles for article (PubMed ID: 23132699)
1. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study.
Thomas D; Tsolakis AV; Grozinsky-Glasberg S; Fraenkel M; Alexandraki K; Sougioultzis S; Gross DJ; Kaltsas G
Eur J Endocrinol; 2013 Feb; 168(2):185-93. PubMed ID: 23132699
[TBL] [Abstract][Full Text] [Related]
2. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
[TBL] [Abstract][Full Text] [Related]
3. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.
Campana D; Nori F; Pezzilli R; Piscitelli L; Santini D; Brocchi E; Corinaldesi R; Tomassetti P
Endocr Relat Cancer; 2008 Mar; 15(1):337-42. PubMed ID: 18310299
[TBL] [Abstract][Full Text] [Related]
4. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
Khuroo MS; Khuroo MS; Khuroo NS
J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
[TBL] [Abstract][Full Text] [Related]
5. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors.
Dakin GF; Warner RR; Pomp A; Salky B; Inabnet WB
J Surg Oncol; 2006 Apr; 93(5):368-72. PubMed ID: 16550587
[TBL] [Abstract][Full Text] [Related]
6. Follow-up of patients with ECL cell-derived tumours.
Sagatun L; Fossmark R; Jianu CS; Qvigstad G; Nordrum IS; Mjønes P; Waldum HL
Scand J Gastroenterol; 2016 Nov; 51(11):1398-405. PubMed ID: 27309188
[TBL] [Abstract][Full Text] [Related]
7. Treatment of ECL cell carcinoids with octreotide LAR.
Fykse V; Sandvik AK; Qvigstad G; Falkmer SE; Syversen U; Waldum HL
Scand J Gastroenterol; 2004 Jul; 39(7):621-8. PubMed ID: 15370681
[TBL] [Abstract][Full Text] [Related]
8. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours.
Grozinsky-Glasberg S; Kaltsas G; Gur C; Gal E; Thomas D; Fichman S; Alexandraki K; Barak D; Glaser B; Shimon I; Gross DJ
Eur J Endocrinol; 2008 Oct; 159(4):475-82. PubMed ID: 18662970
[TBL] [Abstract][Full Text] [Related]
9. Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors.
Namwongprom S; Wong FC; Tateishi U; Kim EE; Boonyaprapa S
Ann Nucl Med; 2008 May; 22(4):237-43. PubMed ID: 18535873
[TBL] [Abstract][Full Text] [Related]
10. One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release.
Fykse V; Sandvik AK; Waldum HL
Scand J Gastroenterol; 2005 Nov; 40(11):1269-74. PubMed ID: 16334435
[TBL] [Abstract][Full Text] [Related]
11. A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Waldum HL
Tumour Biol; 2010 Oct; 31(5):373-80. PubMed ID: 20480408
[TBL] [Abstract][Full Text] [Related]
12. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency.
Woltering EA; Hilton RS; Zolfoghary CM; Thomson J; Zietz S; Go VL; Vinik AI; Vinik E; O'Dorisio TM; Mamikunian G
Pancreas; 2006 Oct; 33(3):250-4. PubMed ID: 17003646
[TBL] [Abstract][Full Text] [Related]
13. Efficient symptomatic control of carcinoid tumors with somatostatin in patients with disease progression under alpha-interferon therapy.
Boehme MW; Schmidt-Gayk H; Bihl H; Eisenhut M; Herfarth CH; Kommere B; Raeth U
Hepatogastroenterology; 1995; 42(6):1053-61. PubMed ID: 8847018
[TBL] [Abstract][Full Text] [Related]
14. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis.
Massironi S; Zilli A; Fanetti I; Ciafardini C; Conte D; Peracchi M
Dig Liver Dis; 2015 Nov; 47(11):978-83. PubMed ID: 26321479
[TBL] [Abstract][Full Text] [Related]
15. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
Ćwikła JB; Bodei L; Kolasinska-Ćwikła A; Sankowski A; Modlin IM; Kidd M
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1437-45. PubMed ID: 26348352
[TBL] [Abstract][Full Text] [Related]
16. Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment.
Pregun I; Gergics P; Dabasi G; Igaz P; Racz K; Tulassay Z
Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):476-7. PubMed ID: 19382304
[No Abstract] [Full Text] [Related]
17. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A.
Fossmark R; Sørdal Ø; Jianu CS; Qvigstad G; Nordrum IS; Boyce M; Waldum HL
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1067-75. PubMed ID: 23072686
[TBL] [Abstract][Full Text] [Related]
18. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
19. Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report.
Eckhauser FE; Lloyd RV; Thompson NW; Raper SE; Vinik AI
Surgery; 1988 Dec; 104(6):1046-53. PubMed ID: 3194832
[TBL] [Abstract][Full Text] [Related]
20. Risk factors of lymph node metastasis in patients with gastric neuroendocrine tumor with normal serum gastrin level.
Jung JH; Choi KD; Koh YW; Park YS; Jung HY; Lee GH; Song HJ; Kim DH; Choi KS; Lee JH; Ahn JY; Kim MY; Bae SE; Kim JH
Hepatogastroenterology; 2015; 62(137):207-13. PubMed ID: 25993755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
